|
| Thursday, October 17, 2024 |
|
|
A Joint Regional Cohort Study by Shimadzu, Eisai, Oita University, and Usuki City Medical Association |
| Shimadzu Corporation, Eisai Co., Ltd., Oita University, and Usuki City Medical Association have demonstrated the utility of blood biomarkers in predicting the accumulation of amyloid beta (Abeta)(1) in the brain, a noted cause of Alzheimer's disease(2), in a cohort study conducted in Usuki City, Oita from November 2022. more info >> |
|
|
Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in Australia |
| Eisai Co., Ltd. and Biogen Inc. announced today that the Therapeutic Goods Administration (TGA) of Australia issued a public statement about the initial decision not to register the humanized anti-solubleaggregated amyloid-beta (Abeta) monoclonal antibody lecanemab for the treatment of patients with mild cognitive impairment (MCI)due to Alzheimer's disease (AD) and mild AD dementia. more info >> |
|
| Wednesday, October 16, 2024 |
|
|
Amyotrophic Lateral Sclerosis Treatment "Rozebalamin(R) for Injection 25 mg" Receives The Good Design Award 2024 for Light- Proof Vial Packaging |
| Eisai Co., Ltd. announced today that amyotrophic lateral sclerosis (ALS) treatment "Rozebalamin(R) for Injection 25 mg" (mecobalamin) has received the Good Design Award 2024 (by the Japan Institute of Design Promotion) for its light-proof vial packaging. more info >> |
|
| Tuesday, October 8, 2024 |
|
|
"Urece Tablets" (Dotinurad) Approved In Thailand For Gout And Hyperuricemia |
| Eisai Co., Ltd. announced today that it has received approval for "URECE Tablets" (dotinurad) in Thailand as a treatment for gout and hyperuricemia. more info >> |
|
| Wednesday, October 2, 2024 |
|
|
Eisai Commences Business Activities At New Pharma Sales Subsidiary In Saudi Arabia |
| Eisai Co., Ltd. announced today that fully-fledged operations and business activities have begun at Eisai Pharmaceuticals Single Person Limited Liability Company (Eisai Saudi Arabia), a pharmaceutical sales subsidiary recently established in Riyadh in the Kingdom of Saudi Arabia (Saudi Arabia). more info >> |
|
| Tuesday, September 24, 2024 |
|
|
Rozebalamin(R) for Injection 25 mg (Mecobalamin) Approved in Japan for Amyotrophic Lateral Sclerosis |
| Eisai Co., Ltd. announced today that it has obtained manufacturing and marketing authorization approval for amyotrophic lateral sclerosis (ALS) treatment "Rozebalamin for Injection 25 mg" (mecobalamin) in Japan as a treatment for slowing progression of functional impairment in amyotrophic lateral sclerosis. more info >> |
|
|
Anticancer Agent "Tasfygo(R) Tablets 35mg" (Tasurgratinib Succinate) Approved in Japan for Biliary Tract Cancer with FGFR2 Gene Fusions or Rearrangements |
| Anticancer Agent "Tasfygo(R) Tablets 35mg" (Tasurgratinib Succinate) Approved in Japan for Biliary Tract Cancer with FGFR2 Gene Fusions or Rearrangements more info >> |
|
| Tuesday, September 17, 2024 |
|
|
LENVIMA(R) (lenvatinib) Plus KEYTRUDA(R) (pembrolizumab) in Combination With Transarterial Chemoembolization (TACE) Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC) |
| These late-breaking data were presented for the first time on September 14 (Central European Summer Time) during a Presidential Symposium at the European Society for Medical Oncology (ESMO) Congress 2024 (Presentation #LBA3). more info >> |
|
| Thursday, September 5, 2024 |
|
|
Eisai Accelerates Progress in Oncology Research with New Data at ESMO Congress 2024 |
| Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio and pipeline during the European Society for Medical Oncology (ESMO) Congress 2024, which is taking place virtually and in-person in Barcelona, Spain from September 13 to 17. more info >> |
|
| Monday, September 2, 2024 |
|
|
Eisai Announces Status Relating to Acquisition of Own Shares |
| Eisai Co., Ltd. announced today that it has acquired its own shares based on Article 40 of its Articles of Incorporation pursuant to the provisions of Article 459, paragraph 1 of the Companies Act. more info >> |
|
|
|
